OCI NV (OCI.AS)

NL0010558797 - Common Stock

23.17  -0.08 (-0.34%)

Fundamental Rating

2

OCI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 63 industry peers in the Chemicals industry. Both the profitability and financial health of OCI have multiple concerns. OCI is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year OCI has reported negative net income.
OCI had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: OCI reported negative net income in multiple years.
In the past 5 years OCI always reported a positive cash flow from operatings.

1.2 Ratios

The Return On Assets of OCI (-7.10%) is worse than 79.03% of its industry peers.
The Return On Equity of OCI (-68.84%) is worse than 91.94% of its industry peers.
Industry RankSector Rank
ROA -7.1%
ROE -68.84%
ROIC N/A
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of OCI (6.73%) is worse than 88.71% of its industry peers.
OCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 6.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

OCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCI remains at a similar level compared to 1 year ago.
Compared to 5 years ago, OCI has more shares outstanding
OCI has a better debt/assets ratio than last year.

2.2 Solvency

OCI has an Altman-Z score of 0.83. This is a bad value and indicates that OCI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of OCI (0.83) is worse than 83.87% of its industry peers.
The Debt to FCF ratio of OCI is 30.10, which is on the high side as it means it would take OCI, 30.10 years of fcf income to pay off all of its debts.
With a Debt to FCF ratio value of 30.10, OCI perfoms like the industry average, outperforming 40.32% of the companies in the same industry.
A Debt/Equity ratio of 2.51 is on the high side and indicates that OCI has dependencies on debt financing.
With a Debt to Equity ratio value of 2.51, OCI is not doing good in the industry: 96.77% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.51
Debt/FCF 30.1
Altman-Z 0.83
ROIC/WACCN/A
WACC5.68%

2.3 Liquidity

A Current Ratio of 1.58 indicates that OCI should not have too much problems paying its short term obligations.
The Current ratio of OCI (1.58) is worse than 67.74% of its industry peers.
OCI has a Quick Ratio of 1.55. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
OCI has a better Quick ratio (1.55) than 70.97% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.55

1

3. Growth

3.1 Past

The earnings per share for OCI have decreased strongly by -111.52% in the last year.
The Revenue for OCI has decreased by -53.13% in the past year. This is quite bad
Measured over the past years, OCI shows a decrease in Revenue. The Revenue has been decreasing by -9.61% on average per year.
EPS 1Y (TTM)-111.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%336.11%
Revenue 1Y (TTM)-53.13%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-10.72%

3.2 Future

The Earnings Per Share is expected to grow by 22.03% on average over the next years. This is a very strong growth
Based on estimates for the next years, OCI will show a very negative growth in Revenue. The Revenue will decrease by -15.48% on average per year.
EPS Next Y146.14%
EPS Next 2Y90.24%
EPS Next 3Y59.2%
EPS Next 5Y22.03%
Revenue Next Year-33.54%
Revenue Next 2Y-14.48%
Revenue Next 3Y-7.14%
Revenue Next 5Y-15.48%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 19.79, OCI is valued on the expensive side.
OCI's Price/Forward Earnings is on the same level as the industry average.
OCI's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 20.22.
Industry RankSector Rank
PE N/A
Fwd PE 19.79

4.2 Price Multiples

OCI's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 64.29
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OCI's earnings are expected to grow with 59.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y90.24%
EPS Next 3Y59.2%

0

5. Dividend

5.1 Amount

OCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OCI NV

AMS:OCI (6/21/2024, 7:00:00 PM)

23.17

-0.08 (-0.34%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.89B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.79
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.1%
ROE -68.84%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 6.73%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 2.51
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.58
Quick Ratio 1.55
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-111.52%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y146.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-53.13%
Revenue growth 3Y-17.33%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y